Clinical Trials Logo

Diabetes Mellitus, Type 2 clinical trials

View clinical trials related to Diabetes Mellitus, Type 2.

Filter by:

NCT ID: NCT01726114 Completed - Diabetes Mellitus Clinical Trials

A Clinical Study of the C8 MediSensors Optical Glucose Monitor™

Spectrum
Start date: June 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to compare glucose measurements from the C8 MediSensors non-invasive Optical Glucose Monitor™ System to blood glucose measurements from the Yellow Springs Instrument(YSI) blood glucose analyzer.

NCT ID: NCT01725815 Completed - Hypertension Clinical Trials

The Health Access and Recovery Peer Program

HARP
Start date: June 2011
Phase: N/A
Study type: Interventional

Individuals with serious mental illnesses (SMI) face high rates of medical comorbidity as well as challenges in managing these conditions. A growing workforce of certified peer specialists is available to help these individuals more effectively manage their health and health care. However, there is little existing research examining the effectiveness of peer-led medical self-management programs for this population. in this trial, participants were randomized to either the Health and Recovery Peer program (HARP), a medical disease self-management program led by certified peer specialists, or to care as usual. Assessments were conducted at baseline, 3 months, and 6 months.

NCT ID: NCT01724645 Completed - Clinical trials for Diabetes Mellitus, Type 2

Beneficial Effects of Korean Traditional Diets in Subjects With Hypertension and Type 2 Diabetes

Start date: September 2010
Phase: N/A
Study type: Interventional

This trial is being conducted to look for following changes when Korean traditional diets is taken in subjects with hypertension and type 2 diabetes: To evaluate the improvement of the controlling fasting blood glucose and glycated hemoglobin. To assess the controlling blood pressure and heart rate. To evaluate the influence on cardiovascular risk factor, Triglyceride, cholesterol, High Density Lipoprotein-cholesterol and Low-Density Lipoprotein-cholesterol. To evaluate the influence on Gamma-Glutamyl Transpeptidase. To evaluate the influence on Cardiovascular risk factor. To evaluate the influence on valsava score, breathing score and upright score.

NCT ID: NCT01724515 Completed - Diabetes Clinical Trials

PGC-1 and Mitochondrial Dysfunction in Diabetes

Start date: September 2012
Phase: N/A
Study type: Interventional

The purpose of this study is determine if you have too much fat in your body that it will decrease the conversion of food energy into energy that your body can use.

NCT ID: NCT01724502 Completed - Diabetes Clinical Trials

Mitochondrial Dysfunction in Diabetes

PGC-1
Start date: September 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether insulin resistance is accompanied by "exercise resistance". Investigators will use mass spectrometry and proteomics analysis to test the hypothesis is that a bout of exercise that increases mitochondrial protein abundance in lean, healthy individuals is less effective in insulin resistant patients.

NCT ID: NCT01720446 Completed - Clinical trials for Diabetes Mellitus, Type 2

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

SUSTAIN™ 6
Start date: February 21, 2013
Phase: Phase 3
Study type: Interventional

This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovascular events (MACE) in this trial and the remaining research programme. The incidence of MACE will be monitored throughout the trial which will be terminated according to plan when pre-specified stopping criteria are met.

NCT ID: NCT01720303 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

Start date: September 19, 2002
Phase: Phase 4
Study type: Interventional

This trial is conducted in Asia. The aim of this trial is to compare oral anti-diabetic drug (OAD) combined with insulin vs. insulin alone in subjects with type 2 diabetes not adequately controlled on the current OAD therapy.

NCT ID: NCT01720290 Completed - Clinical trials for Diabetes Mellitus, Type 2

Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes

Start date: July 25, 2002
Phase: Phase 4
Study type: Interventional

This trial is conducted in Asia. The aim of this trial is to compare repaglinide and metformin administered alone or in combination in subjects with type 2 diabetes.

NCT ID: NCT01719640 Completed - Clinical trials for Diabetes Mellitus, Type 2

MSC and MC in Type 2 Diabetes Mellitus

Start date: January 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Cell injury in human islets induced by non-immune mediated inflammation occur in vitro upon hyperglycemia in type 2 diabetes mellitus. Infusion of autologous bone marrow mononuclear cells (MCs) is an emerging therapeutic approach for DM, which showed promising outcomes with mild side effects. Infusion of MCs and autologous bone marrow mesenchymal stem cells in combination might exert enhanced repairing effects. We hypothesized that infusion of these two classes of cells might provide multiple signals for regeneration and improve recovery from inflammation-induced lesion. The effects might be maximized by intra-arterial pancreatic infusion.

NCT ID: NCT01719003 Completed - Clinical trials for Diabetes Mellitus, Type 2

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Start date: October 2012
Phase: Phase 3
Study type: Interventional

This study will investigate the efficacy and safety of two doses (high and low) of empagliflozin in combination with metformin (500 mg and 1000 mg) administered twice daily in patients with type 2 diabetes mellitus (T2DM). Study will compare four dose combinations of empagliflozin + metformin versus each individual component after 24 weeks of treatment.